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Abstract Angioimmunoblastic T-cell lymphoma (AILT)
represents a subset of T-cell lymphomas but resembles an
autoimmune disease in many of its clinical aspects. Despite
the phenotype of effector T-cells and high expression of
FAS and CTLA-4 receptor molecules, tumor cells fail to
undergo apoptosis. We investigated single nucleotide poly-
morphisms (SNPs) of the FAS and CTLA-4 genes in 94
peripheral T-cell lymphomas. Although allelic frequencies
of some FAS SNPs were enriched in AILT cases, none of
these occurred at a different frequency compared to healthy
individuals. Therefore, SNPs in these genes are not
associated with the apoptotic defect and autoimmune
phenomena in AILT.
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Introduction
Angioimmunoblastic T-cell lymphoma (AILT) is character-
ized by a systemic lymphoproliferative disorder, general-
ized lymphadenopathy, and immunologic abnormalities.
Originally, it was debated whether the disease should be
considered a lymphoma or, alternatively, an abnormal
hyperimmune reaction because the fatal outcome was
mostly attributed to severe infectious complications rather
than to the lymphoproliferation itself. Besides a dispersed
cellular infiltrate of atypical lymphoid cells, predominant
histological features of AILT include an inflammatory
background of plasma cells and eosinophils as well as a
proliferation of “arborizing” vessels and follicular dendritic
cells. AILT patients frequently exhibit autoimmune phe-
nomena such as cold agglutinins with hemolytic anemia,
circulating immune complexes, anti-smooth muscle anti-
bodies, and positive rheumatoid factor [1].
Inrecentyears,clonalityanalysisinAILThasdemonstrated
a clonal expansion of T-cells in most cases. Furthermore,
studies focused on the immunophenotype of the tumor cells
including their correlation with normal T-cell counterparts [2],
underlying cytogenetic alterations, and associations with
Epstein–Barr virus (EBV) infections and EBV-driven accom-
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Karlsruhe, Germanypanying B-cell proliferations. Based on the expression of
CXCL13 and CD10, tumor cells in AILT were correlated to
germinal center B-helper T-cells, which represent a popula-
tion of follicular T-cells constituting a crucial checkpoint for
B-cell differentiation and for the maintenance of B-cell
tolerance in the periphery [3–5]. However, few approaches
have been taken to explain the autoimmune features that are
prominent in many AILT patients.
We could recently demonstrate that the neoplastic T-cells
in AILT homogeneously correspond to effector cells [2]
who are by their natural fate destined to die from apoptosis.
This is in contrast to peripheral T-cell lymphomas, not
otherwise specified (PTCL-NOS) which correspond to
central memory T-cells, a long-living T-cell population that
develops by “below threshold” antigen stimulation or when
polarizing cytokines are missing [6]. The programmed cell
death in effector cells is indispensable for the termination of
physiological immune reactions [7], and, interestingly, the
tumor cells in AILT express the two molecules FAS and
CTLA-4 which are mainly regarded as mediators of
apoptosis induction in lymphocytes [8]. Furthermore, the
neoplastic T-cells in most of the AILTs express CD10 [9],
which is a neutral peptidase expressed in reactive T-cells
and some neoplastic B-cells after induction of apoptosis
[10–12]. BCL-2, an anti-apoptotic molecule, has been
shown to be overexpressed in different B-cell lymphomas
[13], while it is consistently negative in AILT [2]. Taken
together, these data raise the question, why the neoplastic T-
cells in AILT do not undergo apoptosis.
In mouse models, pathological features resembling those
in AILT can be induced by introducing mutations of the
FAS [14], the CTLA-4 [15], or effector-caspase genes [16],
respectively. Moreover, the morphological changes in
lymph nodes of patients with an autoimmune lymphopro-
liferative syndrome (ALPS), a disease caused by hereditary
mutations in the FAS gene [17, 18], can mimic the histology
of AILT.
FAS, a homotrimeric transmembrane receptor, is an
important mediator for the downregulation of immune
responses [19] by inducing apoptosis of antigen-primed
lymphocytes, including those with autoimmune potential
[20]. The gene-encoding FAS contains nine exons [21], and
dominant, heterozygous mutations in the FAS gene cause
the above-mentioned ALPS phenotype. These patients
show a defect in FAS-mediated apoptosis in lymphocytes
and a pathological expansion of double negative T-cells
expressing an αβ T-cell receptor [22–24]. Impairment of
lymphocyte apoptosis, in general, underlies a variety of
autoimmune phenomena [22, 25, 26] and predisposes to
diverse lymphomas [26]. FAS mutation itself has also been
suggested as contributing factor in the etiology of other
diseases including autoimmune phenomena [23, 27–37]a s
well as malignant lymphomas [36] and solid tumors [38].
Several studies described single nucleotide polymorphisms
(SNPs) of the FAS gene to be associated with susceptibility
to autoimmune diseases [39–45] as well as cancer [46].
CTLA-4 is a negative regulator of T-cell activation [47]
which interacts with its ligands CD80/86 and competes—
albeit with a much higher affinity—against CD28 [48, 49].
The CTLA-4 gene has been a primary candidate for a genetic
susceptibility to autoimmune diseases [50–54] and to a
certain extent to non-Hodgkin’sl y m p h o m a s[ 55]. Further-
more, there are indications for a role of CTLA-4 promoter
variants in cancer in general [56], and, additionally, one
particular polymorphism in the promoter region has been
shown to affect the gene expression level of CTLA-4 [57].
SNPs, themselves, do not cause diseases, but they can help
to determine the likelihood that someone will develop a
particular disease. Most SNPs are silent, i.e., they do not exert
a discernible effect on gene function or phenotype. They can,
however, have important consequences for the individual
susceptibility to a certain disease or to reactions to certain
pharmaceuticals. In addition to changes in single genes that
affectdisease risk, itisthought thatparticular combinations of
SNPs located across multiple genes contribute to a predispo-
sition for developing a certain disease [58]. Allelic variations
in promoter regions could potentially affect the gene
expression quantitatively or qualitatively by altering tran-
scription factor binding sites or other regulatory domains.
Given that AILT is frequently associated with autoim-
mune phenomena, and given that the tumor cells of AILT
show an effector phenotype but—despite their expression
of FAS and CTLA-4—fail to undergo apoptosis, we
investigated whether polymorphisms of the FAS and
CTLA-4 genes may be responsible for these features.
Materials and methods
Subjects and SNPs
We selected 53 AILT and 41 PTCL-NOS cases from our
archives based on the availability of frozen lymph node
specimens or peripheral blood lymphocytes. All cases had
been diagnosed according to the World Health Organization
classification [1] and were characterized by an extensive
immunohistochemical marker panel. All of these 94
lymphomas were analyzed for the presence of the five
CTLA-4 gene polymorphisms (see below). As controls, we
used data of 173 healthy blood donors that were published
previously [54].
In addition, a subset of tumors (ten AILT and ten PTCL-
NOS cases) was selected randomly for the analysis of the
29 FAS gene polymorphisms and three mutations (see
below). As a control cohort, we used the data population
PDR90 (NCBI Single Nucleotide Polymorphism Database,
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which comprises SNP information in a global population
of 90 individuals. To avoid false positive results due to
major differences in sample numbers, ten individuals were
selected randomly from this database using the “Random
Function” in MS Excel. Some of the examined SNPs or
mutations were not included in the PDR90 study; thus,
control data were obtained from the literature (see refer-
ences in Table 1). As a general approach, we preferentially
chose SNPs which had already been described in correla-
tion with relevant diseases (Table 1). Furthermore, we
included one additional SNP that was detected during our
sequence analyses but had not been cited in the literature
previously. We compared allelic frequencies between AILT,
PTCL-NOS, and healthy control samples for all 29 FAS
SNPs and three mutations as well as the genotypes for 20 of
these SNPs for which control data was available in the
dbSNP population PDR90.
DNA extraction and genotyping
Genomic DNA was extracted from frozen lymph node
tissue or from peripheral blood lymphocytes using the
QIAamp DNA Mini Kit (Qiagen, Hilden, Germany).
29 FAS SNPs and three mutations (Table 1)w e r e
analyzed by polymerase chain reaction (PCR) amplification
of the exon and intron sections or the promoter and 3′UTR
regions, respectively. PCR products were sequenced and
compared to Genbank accession numbers D31968.1 and
AY450925. PCR- and sequencing-primers used were either
according to the indicated literature or newly designed
(Table 1). The DNA template, 50 ng in a final volume of
25 μl, was amplified in a reaction mixture containing a final
concentration of 0.5 μM primer, 0.2 mM dNTPs (Fermen-
tas, St.Leon-Rot, Germany), and 1× Taq polymerase buffer
with 1.5 mM MgCl2 and 0.5 U Taq polymerase (Taq DNA
polymerase, recombinant, Invitrogen, Karlsruhe, Germany).
PCR reactions were run for 35 cycles in a thermocycler
Table 1 Overview of investigated FAS SNPs including references
with PCR conditions
Region Polymorphism Reference
Promoter −1377g>a [67]
Rs2234767
Promoter g-1221C>G [68]
a
Promoter g-1194A>T [68]
a
Promoter −691t>c [67]
Rs2234768
Promoter −671a>g [67]
Rs1800682
Promoter g-397C>T [67, 68]
a
Rs5030765
Promoter
c g-295Ains [67, 68]
a
Promoter
c g-129Cins [67, 68]
a
Exon1 c.161A>G [67]
Rs5030766
Exon2 c.240G>A [67]
Rs3218619
Exon2 c.297T>C [67]
Rs9333296
Exon2 c.335G>A [67]
Rs3218621
Exon2 c.377G>A [67]
Rs3218613
Exon2 IVS2
+176C>T
[67, 69]
a
Rs2296603
Exon3 c.416A>G [67]
Rs3218612
Intron3
c g435Gdel [67, 68]
Intron3 c.528(+46)c>t [67]
Rs2296601
Intron3 c.528(+80)
g>c
[67]
Rs3218618
Exon4 c.559C>T [67]
Rs3218614
Exon4 c.563G>A [67]
Rs28362318
Intron4 A/T(735)G/C [42]
a
Rs3781202
Intron4 IVS4+699 [42]
a, b
Rs9658757
Intron5 c.699(+16)c>t [67]
Rs3218620
Intron5 c.699(+82)
c>g
[67]
Rs2296600
Exon6 c.744A>G [67]
Rs28362322
Exon7 c.836C>T [67]
Rs2234978
Intron7 IVS7+312 [69], forward[67], reverse:
agaaagtaacaggccggatgtg
a Rs3740281
Intron8 c.870(+75)
g>a
[67]
Rs3218615
Exon9 c.1108C>T [67]
Rs3218611
3′UTRa g1107A>T [68]
Rs1051070
Table 1 (continued)
Region Polymorphism Reference
3′UTR g1307T>C [68]
Rs9658776
3′UTR g1626T>C [68]
Rs1468063
Different nomenclature inclusive notation is used because poly-
morphisms were named according to the cited literature. Allele count
and frequencies were taken from the denoted literature or, if not
existent there, from dbSNP.
aPCR primer for and rev were used for sequencing
bno literature found
cMutation
J Hematopathol (2008) 1:11–21 13Table 2 Allelic frequencies of SNPs and mutations in the human FAS gene
Allele count and frequencies (%) Significance p
AILT n=10 PTCL-NOS
n=10
Controls
a AILT/
PTCL-NOS
Co/
AILT
Co/
PTCL-NOS
−1377g>a G A G A G A
18 90 2 10 18 90 2 10 244 87.14 36 12.86 1 0.71 0.71
g-1221C>G C G C G C G
20 100 0 0 20 100 0 0 20 100 0 0 n.p. n.p. n.p.
g-1194A>T A T A T A T
20 100 0 0 20 100 0 0 20 100 0 0 n.p. n.p. n.p.
−691t>c T c t c t C
20 100 0 0 16 80 4 20 19 95 1 5 0.035* 0.311 0.152
−671a>g A g a g a g
10 50 10 50 10 50 10 50 9 45 11 55 1 0.752 0.752
g-397C>T C T C T C T
20 100 0 0 20 100 0 0 20 100 0 0 n.p. n.p. n.p.
g-295Ains mu Ø mu Ø mu Ø
0 0 20 100 0 0 20 100 0 0 20 100 n.p. n.p. n.p.
g-129Cins mu Ø mu Ø mu Ø
0 0 20 100 0 0 20 100 0 0 20 100 n.p. n.p. n.p.
c.161A>G A G A G A G
20 100 0 0 20 100 0 0 292 98.65 4 1.351 n.p. 0.601 0.601
c.240G>A G A G A g A
20 100 0 0 20 100 0 0 20 100 0 0 n.p. n.p. n.p.
c.297T>C T C T C T C
20 100 0 0 20 100 0 0 296 100 0 0 n.p. n.p. n.p.
c.335G>A G A G A g A
20 100 0 0 20 100 0 0 20 0 20 0 n.p. n.p. n.p.
c.377G>A G A G A g A
20 100 0 0 18 90 2 10 19 95 1 5 0.147 0,311 0.548
IVS2+176C>T C T C T C T
11 55 9 45 14 70 6 30 11 55 9 45 0.327 1 0.327
c.416A>G A G A G A G
19 95 1 5 17 85 3 15 17 85 3 15 0.29 0.292 1
g435Gdel mu Ø mu Ø mu Ø
0 0 20 100 0 0 20 100 2 10 18 90 n.p. 0.147 0.147
c.528(+46)c>t C t c t c t
18 90 2 10 19 95 1 5 18 90 2 10 0.548 1 0.548
c.528(+80)g>c G c g g c
20 100 0 0 20 100 0 0 20 100 0 0 n.p. n.p. n.p.
c.559C>T C T C T C T
20 100 0 0 20 100 0 0 20 100 0 0 n.p. n.p. n.p.
c.563G>A G A G A g A
20 100 0 0 20 100 0 0 279 99.64 1 0.357 n.p. 0.789 0.789
IVS4+699T>C T C T C T C
19 1 14 6 18 90 2 10 0.038* 0.548 0.114
IntIVA/T(735)
G/C
AG AG A G
9 45 11 55 4 20 16 80 8 40 10 60 0.091 0.749 0.168
c.699(+16)c>t C T C T C T
20 100 0 0 20 100 0 0 19 95 1 5 n.p. 0.311 0.311
c.699(+82)c>g C g c g c g
11 55 9 45 16 80 4 20 12 60 8 40 0.091 0.749 0.168
c.744A>G A G A G A G
20 100 0 0 20 100 0 0 291 99.66 1 0.342 n.p. 0.793 0.793
c.836C>T C T C T C T
13 65 7 35 14 70 6 30 15 75 5 25 0.736 0.49 0.723
14 J Hematopathol (2008) 1:11–21(Mastercycler gradient, Eppendorf, Wesseling-Berzdorf,
Germany). After 3 min denaturation at 94°C, each cycle
consisted of 45 s at 94°C, 30 s at the assigned annealing
temperature and 1 min 30 s at 72°C followed by a final
extension step of 10 min at 72°C. PCR products were
purified (QIAquick PCR purification kit Qiagen, Hilden,
Germany) and aliquots of 7 μl were used for sequencing
analysis with 1 μM of the respective primer and 2 μlo f
BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied
Biosystems, Foster City, CA, USA) in a final volume of
10 μl. Samples were analyzed in a 3130×l Genetic
Analyzer (Applied Biosystems, Foster City, CA, USA).
We investigated 6 promoter region-, 13 exon-, 10 intron-
and three 3′UTR-SNPs. Sequencing peaks at the location of
a SNP showed either one peak indicating homozygosity or
two equal lower peaks indicating heterozygosity.
The CTLA-4 SNP genotypes and allele frequencies of
three promoter-SNPs (−1722T/C, −1661A/G, and −318C/T),
one exon-SNP (+49A/G), and one 3′UTR-SNP (CT60A/G)
were identified following previously described polymerase
chain reaction or restriction fragment length polymorphism
protocols [53, 59, 60].
Different nomenclature of SNPs including their annota-
tion is used because polymorphisms were strictly named
according to the cited literature.
FAS and CTLA-4 staining by immunohistochemistry
To investigate a possible association between the respective
SNPs and the FAS or CTLA-4 expression on the protein
level, we performed FAS (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) and CTLA-4 (BD Biosciences, San Diego,
CA, USA) double fluorescence stains in combination with
an antibody directed against the respective T-cell receptor
(TCR) Vβ-segment rearranged and expressed by the
neoplastic T-cells as previously described [61]. Using this
approach, 9/10 AILT and 10/10 PTCL-NOS cases analyzed
for FAS SNPs were investigated. Fluorescence images were
evaluated using confocal laser scanning microscopy (Leica
TCS2, Leica, Bensheim, Germany). One AILT case had to
be excluded from the analysis because no antibody against
the respective TCRVβ-segment was available.
Statistical analysis
Allele frequencies were compared with the chi-square test.
The genotype frequencies between different groups of
subjects were compared with chi-square correlation calculat-
ed on 2×2 contingency tables. A p value less than 0.05 was
considered statistically significant. Staining signal intensity
was statistically compared with Spearman rank correlation to
diagnoses or SNP haplotype on 2×2 contingency tables.
SNPswithminorallelefrequencies≥5%wereestimatedby
the expectation maximization algorithm as determined by the
Haploview program [62]. Logarithm of the odds ratio scores
between 2.2 and 3.6 were considered suggestive [63].
Results
FAS gene polymorphisms
Altogether, we analyzed 29 SNPs and three mutations in the
coding and flanking regions of the FAS gene (six promoter-,
Table 2 (continued)
Allele count and frequencies (%) Significance p
AILT n=10 PTCL-NOS
n=10
Controls
a AILT/
PTCL-NOS
Co/
AILT
Co/
PTCL-NOS
IVS7+312C>T C T C T C T
19 95 1 5 14 70 6 30 18 90 2 10 0.038* 0.548 0.114
c.870(+75)g>a G a g a g a
20 100 0 0 20 100 0 0 19 95 1 5 n.p. 0.311 0.311
c.1108C>T C T C T C T
20 100 0 0 20 100 0 0 20 100 0 0 n.p. n.p. n.p.
g1107A>T A T A T A T
17 85 3 15 18 90 2 10 19 95 1 5 0.633 0.292 0.548
g1307T>C T C T C T C
19 95 1 5 18 90 2 10 13 85 3 15 0.548 0.292 0.633
g1626C>T C T C T C T
18 90 2 10 19 95 1 5 18 90 2 10 0.548 1 0.548
n.p. Not possible, mu mutation, co controls
aControl data was used from dbSNP population PDR90 (global group) if available, SNPs lacking these data were compared to literature as
annotated in Table 1
*P<0.05
J Hematopathol (2008) 1:11–21 1513 exon-, ten intron-, three 3′UTR-SNPs; Table 1). One of
the SNPs (IVS4+699T>C) was discovered during our
evaluation of the data and was found in the dbSNP database;
however, this SNP has not been described in the literature
before. Overall, we could not detect SNPs at FAS splice sites
among our sequences.
Three geneloci(−691t>c,IVS4+699T>C,IVS7+312C>T)
showed differences in allelic frequencies when AILT and
PTCL-NOS cases were compared; however, these SNPs did
not differ statistically in their allelic frequency values when
comparedtothecontrolcases.ForfourSNPs(IVS2+176C>T,
IVS4+699T>C, A/T(735)G/C, c.699(+82)c>g), we were able
to detect differences in their genotype frequencies when all
threegroupswerecompared(Tables2 and 3, P values in bold
type).
Cluster analysis of all three groups for the combined
genotypes of the previously mentioned 20 SNPs revealed one
subgroup with a highdegree of similaritieswhichcontained7/
Table 3 Genotypes of SNPs in the FAS gene
PTCL-NOS AILT Controls Significance (P)
−691t>c TT TC CC TT TC CC TT TC CC
7 2 1 10 0 0 9 1 0 0.201
−671a>g AA AG GG AA AG GG AA AG GG
3 4 3 1 8 1 3 3 4 0.223
c.240G>A GG GA AA GG GA AA GG GA AA
10 0 0 10 0 0 10 0 0 n.p.
c.335G>A GG GA AA GG GA AA GG GA AA
10 0 0 10 0 0 10 0 0 n.p.
c.377G>A GG GA AA GG GA AA GG GA AA
9 0 1 10 0 0 9 1 0 0.396
IVS2+176C>T CC CT TT CC CT TT CC CT TT
6 2 2 1 9 0 3 5 2 0.034*
c.416A>G AA AG GG AA AG GG AA AG GG
7 3 0 9 1 0 7 3 0 0.475
c.528(+46)c>t CC CT TT CC CT TT CC CT TT
9 1 0 8 2 0 8 2 0 0.787
c.559C>T CC CT TT CC CT TT CC CT TT
10 0 0 10 0 0 10 0 0 n.p.
IVS4+699T>C TT TC CC TT TC CC TT TC CC
5 4 1 9 1 0 8 0 0 0.054
a
IntIVA/T(735) G/C AA AG GG AA AG GG AA AG GG
1 2 7 0 9 1 1 6 3 0.034*
c.699(+16)c>t CC CT TT CC CT TT CC CT TT
10 0 0 10 0 0 9 1 0 0.355
c.699(+82)c>g CC CG GG CC CG GG CC CG GG
7 2 1 1 9 0 3 6 1 0.034*
c.836C>T CC CT TT CC CT TT CC CT TT
5 4 1 3 7 0 6 3 1 0.426
IVS7+312C>T CC CT TT CC CT TT CC CT TT
5 4 1 9 1 0 8 2 0 0.269
c.870(+75)g>a GG GA AA GG GA AA GG GA AA
10 0 0 10 0 0 9 1 0 0.355
c.1108C>T CC CT TT CC CT TT CC CT TT
10 0 0 10 0 0 10 0 0 n.p.
g1107A>T AA AT TT AA AT TT AA AT TT
8 2 0 7 3 0 9 1 0 0.535
g1307T>C TT TC CC TT TC CC TT TC CC
8 2 0 9 1 0 7 3 0 0.535
g1626C>T CC CT TT CC CT TT CC CT TT
9 1 0 8 2 0 8 2 0 0.787
Control data was obtained from dbSNP population PDR90 (global group)
n.p. Not possible
aBorderline significance
*P<0.05
16 J Hematopathol (2008) 1:11–2110oftheAILTcases(Fig.1). The remaining three AILTcases
were more closely linked to PTCL-NOS or control cases.
To detect a possible effect of the FAS SNP in the
promoter region (−691t>c) on gene expression in AILT
cases, FAS-staining was performed in 10/10 PTCL-NOS
and 9/10 AILT. In general, all AILT tumors showed a
significantly stronger FAS expression compared to most of
the PTCL-NOS (Table 4 and Fig. 2). Performing cluster
analysis of FAS expression and the −691t>c genotype, all
AILT and two PTCL-NOS cases shared the same combi-
nation of parameters (data not shown).
Because complex disease phenotypes including autoim-
munity may be influenced by polymorphisms at multiple
gene loci presumably related to expression levels or the
ability of variant protein domains to interact with functional
partners or substrates, we searched for a potential risk
related to haplotypic differences by performing haplotype
and linkage disequilibrium (LD) analysis. We found LD
among several SNPs with minor allele frequency ≥5% (data
not shown). However, no haplotype blocks emerged.
CTLA-4 gene polymorphisms
We found no significant association of any of the studied
CTLA-4 SNPs with AILT, PTCL-NOS, and control indi-
viduals comparing allelic frequencies or genotypes (Tables 5
and 6). Likewise, cluster analysis of AILT, PTCL-NOS, and
controls for the combined genotypes of the CTLA-4 SNPs
revealed no subgroups (data not shown).
The eight AILT cases that could be investigated showed
a significantly stronger CTLA-4 expression on the protein
level compared to the six PTCL-NOS cases investigated
(Table 4 and Fig. 2). Performing cluster analysis of CTLA-
Fig. 1 Cluster analysis of 20
FAS SNP genotypes with AILT,
PTCL-NOS, and control indi-
viduals. FAS
− cases are framed
and FAS
+ cases are additionally
labelled in grey. The remaining
cases represent controls without
available expression data
Table 4 Staining intensities of FAS and CTLA-4 antibodies in the
tumor cells of AILT and PTCL-NOS
Case no Diagnosis FAS CTLA-4
1 PTCL-NOS + n.p.
2 ––
3 ––
4+ –
5 – n.p.
6 ––
7+ –
8 – n.p.
9 – n.p.
10 ––
11 AILT + –
12 + –
13 + –
14 + +
15 + n.p.
16 + +
17 + +
18 + +
19 + +
p-value 0.00045 0.013
n.p. Not possible because of technical reasons
J Hematopathol (2008) 1:11–21 174 expression and the three CTLA-4 promoter SNP geno-
types, no subgroups were detected that included a signif-
icant subset of one of the lymphoma entities. Comparing
CTLA-4expressionwiththeclusteranalysisperformedonthe
basis of all CTLA-4 genotypes and all cases, a completely
heterogeneous pattern emerged (data not shown).
Discussion
Tumor cells of AILTshow an effector phenotype, which is—in
the non-malignant counterpart—associated with a propensity
to undergo apoptosis. In view of the findings thattumor cells in
AILT patients highly express the proapoptotic molecules FAS
and CTLA-4 and are negative for BCL2, a potent inhibitor of
apoptosis, we wondered if certain SNPs and/or mutations of
the FAS and CTLA-4 genes may be associated with the failure
of the tumor cells to undergo apoptosis. However, no such
associations could be uncovered in this study. Although six
SNPs of the FAS gene showed a differential distribution
between the AILT and PTCL-NOS subgroups, none of the
SNPs appeared to be statistically enriched in comparison to a
normal control population. These six SNPs include the SNP -
691T>C, which is located in the promoter region of the FAS
gene and IVS2+176C>T, which is a silent SNP in exon 2.
The remaining four SNPs are located in various introns of the
FAS gene. Comparing these results with data from the
literature, three SNPs were associated with certain autoim-
mune diseases, such as multiple sclerosis (A/T(735)G/C) or
Sjögren’s syndrome (c.699(+82)c>g and IVS2+176C>T) in
previous reports [42, 43].
To investigate whether the SNP −691T>C located in the
promoter region could potentially lead to a modified
transcription factor binding site and therefore be of
relevance for the expression level of the FAS gene, we
analyzed the FAS expression of the neoplastic T-cells in
AILTand PTCL-NOS by immunohistochemistry. As shown
in Table 4 and in the representative images of Fig. 2,F A S
staining in AILT and PTCL-NOS cases revealed a signif-
icant difference with a significantly higher expression of
FAS among AILT cases. Moreover, cluster analysis includ-
ing only the status of the promoter SNP and the expression
data showed a correlation between this SNP and the FAS
expression in AILT, with all AILT showing the same
Fig. 2 Representative fluores-
cence double stainings of
CTLA4/TCRVβ and FAS/
TCRVβ in PTCL-NOS and
AILT. Upper panel: The tumor
cells in PTCL-NOS (case 10) do
not coexpress CTLA4 (a: green
Vβ 2, red CTLA4) and FAS
(b: green Vβ 2, red FAS).
Lower panel: The tumor cells in
AILT (case 17) show a coex-
pression of CTLA4 (c: green
Vβ 5.1, red CTLA4) and FAS
(d: green Vβ 5.1, red FAS)
18 J Hematopathol (2008) 1:11–21genotype linked to the expression pattern, while PTCL-
NOS cases revealed a heterogeneous pattern regarding
genotype and FAS expression. Interestingly, two of the
three FAS
+ PTCL-NOS cases shared the genotype charac-
teristic of AILT, while five PTCL-NOS cases with the same
genotype were FAS
−. In contrast, the remaining FAS
+
PTCL-NOS case revealed a completely different genotype.
We next addressed the question if the promoter SNP
−691T>Ccouldleadtochangesintranscriptionfactorbinding
sites. Because no reports exist in the literature to date, we
compared the respective sequences with a transcription factor
database (http://www.cbrc.jp/research/db/TFSEARCH.html).
Potential binding sites were found for AML-1a with a score
of 83.4 for allele T and for c-Myc with a score of 80.9 for
binding only allele C, which could allow the speculation that
in AILT, c-Myc does not interact with this location.
Are the quantitative differences in FAS expression
between AILT and PTCL-NOS subgroups attributable to
underlying differences in SNP genotypes? We believe that
this scenario is highly unlikely. First, SNP distributions in
AILT and PTCL-NOS cases did not show statistically
significant differences to their occurrence in normal controls.
Second, tumor cells in AILT and PTCL-NOS correspond to
different subsets of normal T-cell populations [2], which
show physiological variations in their FAS expression.
Therefore, the difference in FAS expression likely only
reflects the distinct expression levels of the physiological
counterparts. Future studies will, therefore, have to address
the exact quantification of the FAS expression across various
physiological differentiation states of T-cells. In addition,
DNA-binding studies with AML-1a and c-Myc and the
different promoter variants could shed light on the question if
and to what extent these transcription factors may play a role
in the regulation of FAS expression.
Because certain SNPs in the CTLA-4 gene can lead to
functional changes, such as modified promoter activity and
lower CTLA-4 surface expression, inefficient processing led
to reduced control of T-cell proliferation and a reduced
soluble CTLA-4 isoform [51, 57, 64, 65], and because some
of these SNPs have been associated with a broad variety of
autoimmune diseases [66], we studied CTLA-4 SNPs in AILT
and PTCL-NOS cases. However, the statistical evaluation of
allelic frequencies and genotypes yielded no correlation
between the presence of a CTLA-4 SNP with either the AILT
or PTCL-NOS subgroup. Additionally, cluster analysis of
genotypes also revealed no subgroups. Even though CTLA-4
Table 6 Genotypes of SNPs in the CTLA-4 gene
AILT PTCL-NOS Controls Significance (P)
−1722T>C TT TC CC TT TC CC TT TC CC
46 7 0 36 4 1 150 21 2 0.83
−1661A>G AA AG GG AA AG GG AA AG GG
36 17 0 30 11 0 111 56 6 0.40
−318C>T CC CT TT CC CT TT CC CT TT
43 8 2 35 5 1 140 29 4 0.93
+49A>G AA AG GG AA AG GG AA AG GG
21 19 13 16 19 6 78 65 30 0.60
CT60A>G AA AG GG AA AG GG AA AG GG
14 20 19 10 21 10 35 95 43 0.28
Table 5 Allelic frequencies of SNPs in the human CTLA-4 gene
Allele count and frequencies (%) Significance p
AILT n=53 PTCL-NOS n=41 Controls n=173 AILT/ PTCL-NOS Co/ AILT Co/ PTCL-NOS
−1722T>C T C T C T C
99 93 7 7 76 93 6 7 321 93 25 7 0.85 0.83 0.98
−1661A>G A G A G A G
89 84 17 16 71 87 11 13 278 80 68 20 0.62 0.40 0.19
−318C>T C T C T C T
94 89 12 11 75 91 7 9 309 89 37 11 0.53 0.86 0.56
+49A>G A G A G A G
61 58 45 42 51 62 31 38 221 64 125 36 0.52 0.24 0.78
CT60A>G A G A G A G
58 55 48 45 41 50 41 50 181 52 165 48 0.52 0.66 0.71
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NOS cases, this again is likely to be explained by the distinct
differentiation states of the normal counterparts of the
neoplastic populations in AILT and PTCL-NOS. This is
supported by comparing CTLA-4 expression to promoter
SNP genotypes and the cluster analysis of all five genotypes,
which did not show any correlation.
Interestingly, in another study, a difference in the occurrence
of the +49AA genotype of the CTLA-4 gene was described
between non-Hodgkin’s lymphoma patients and controls [55].
Four of 44 cases in this study were T-cell lymphomas, but,
unfortunately, the authors did not provide detailed information
on this subset. Thus, results between our and the previously
mentioned study cannot be compared at the present time.
In summary, our study provides evidence that SNPs or
mutations of the FAS and CTLA-4 genes are not responsible
for the failure of the tumor cells in AILT patients to undergo
apoptosis and for the accompanying autoimmune phenom-
ena. Future studies will have to unravel the mechanism by
which the neoplastic population in AILT that appears to have
an effector T-cell phenotype and is equipped with high
expression of the pro-apoptotic molecules FAS and CTLA-4
circumvent the induction of cell death.
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